IMPORTANCE Generalized anxiety disorder (GAD) is poorly understood compared with other anxiety disorders, and debates persist about the seriousness of this disorder. Few data exist on GAD outside a small number of affluent, industrialized nations. No population-based data exist on GAD as it is currently defined in DSM-5.
Although GAD has evolved into a well-defined condition characterized by excessive, uncontrollable worry, the assumption that GAD is associated with relatively minimal impairment has persisted in some circles, with the term "worried well" sometimes used to describe affected individuals. 1, 6 This assumption may partially account for lower clinical and research attention to GAD than to other emotional disorders. 7, 8 Attention to GAD has been especially limited outside a small number of industrialized, affluent countries in which nearly all research on the disorder has been conducted. There is reason to suspect, however, that GAD may be important not only in affluent countries but also in other parts of the world. In fact, GAD might be more common and impairing in lower-income countries given the greater economic and political instability, insecurity of access to basic necessities, and uncertainty about the future that tend to characterize those countries. In line with this hypothesis, lower socioeconomic status is associated with greater mental illness within countries 9,10 ; similar mechanisms could apply across countries as well. Alternatively, GAD might be less prevalent and impairing in lower-income countries. A GAD diagnosis requires worries to be excessive, and this requirement may be met less often in countries where worry corresponds to realistic everyday concerns. Furthermore, other disorders have been observed to manifest more frequently through somatic than cognitive symptoms in non-Western countries, 11, 12 raising the possibility that GAD, which is centrally defined by a cognitive symptom (worry), may be less common in developing than developed countries. Finally, cross-cultural research on other chronic mental disorders suggests that prevalence is often lower and outcomes better in less developed countries, perhaps due to greater provision of support by family and community. 13 We explored these competing hypotheses using data from the World Mental Health (WMH) Survey Initiative, 14 a coordinated series of general population surveys carried out under the auspices of the World Health Organization (WHO). Two features of the surveys are noteworthy for the present study. First, data were collected in 26 countries of varying income levels. This diversity provided an opportunity to isolate universal characteristics of GAD from characteristics that vary across countries. Second, by lifting the DSM-IV hierarchy rule prohibiting the diagnosis of GAD during a mood disorder, the surveys were able to define GAD using DSM-5 criteria. To our knowledge, these results represent the first community epidemiologic data on DSM-5 GAD.
Methods

Samples and Procedures
Respondents were 147 261 adults, ranging in age from 18 to 99 years, who participated in the WMH surveys. Data from 29 surveys in 26 countries are included in this report ( Table 1) . The surveys were fielded between 2001 and 2012 and had a weighted mean response rate of 69.5% (eTable 1 in the Supplement). All surveys included nationally or regionally representative samples of the household population. Sampling and weighting methods are detailed elsewhere. 15 To summarize results across surveys, we used World Bank criteria 16 to classify surveys into 3 country-level income groups: (1) low income and lower-middle income, (2) upper-middle income, and (3) high income. We refer to these groups as low, middle, and high income for ease of presentation. All surveys used the WHO Composite International Diagnostic Interview (CIDI), 17 a validated, fully structured, layadministered interview. Prior to administration in each country, the CIDI was translated, back-translated, and harmonized using standardized procedures. 18 Consistent training and field quality control procedures were established across countries.
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Interviews were administered face-to-face in 2 parts. Part 1, which assessed a core set of mental disorders including GAD, was administered to all respondents. Part 2, which assessed additional disorders, was administered to respondents with a part 1 disorder plus a probability subsample of other respondents. Comorbidity analyses were performed using the part 2 sample, which was weighted to adjust for differential probability of selection into part 2. All other analyses used the part 1 sample. A human subjects review board or ethics committee approved the survey protocol in each country (eAppendix in the Supplement), and all respondents gave informed consent; the mode of consent (written vs oral) varied by survey. The presence and type of compensation also varied among surveys.
was assessed using probing methods that have been demonstrated to improve dating accuracy. 26 Persistence of GAD was estimated indirectly by calculating the proportion of respondents with 12-month GAD among those with the lifetime disorder.
Impairment
Respondents with 12-month GAD were administered an expanded version of the Sheehan Disability Scale 27 to assess role impairments caused by the disorder during the worst month in the year before the interview. Respondents rated the extent of interference with home management, work, close relationships, and social life on separate 0-to-10 scales. We grouped ratings into categories of absent (0), mild (1-3), moderate (4-6), and severe (7-10) impairment for analysis. We also assessed the number of days in the past 12 months during which respondents reported being totally unable to work or carry out usual activities because of GAD.
Comorbid Disorders
Mental disorders other than GAD were diagnosed using DSM-IV criteria. They included other anxiety disorders (ie, panic disorder, agoraphobia, social phobia, specific phobia, posttrau- havior disorders (ie, oppositional defiant disorder, conduct disorder, intermittent explosive disorder, attention-deficit/ hyperactivity disorder, bulimia nervosa, and binge eating disorder), and substance-related disorders (ie, alcohol and drug abuse and dependence).
Other Measures
Sociodemographic variables included respondent age, sex, marital status, educational level, household income (stratified into quartiles within country), and employment status at the time of the interview. Treatment seeking was assessed by asking whether respondents received treatment for any mental health or substance-related problem during the past 12 months. Treatment in 4 sectors was probed: specialty mental health, general medical health, human services, and complementary-alternative medicine.
Statistical Analysis
Cross-tabulations were used to estimate prevalence, comorbidity, impairment, and treatment. Logistic regression and survival analysis were used to examine sociodemographic correlates. 
Results
Prevalence
Across all surveys, the combined lifetime prevalence of GAD was 3.7%, 12-month prevalence was 1.8%, and 30-day prevalence was 0.8% ( 
Sociodemographic Correlates
Around the world, being female, younger than 60 years, and unmarried (previously married or never married) were associated with GAD (eTable 2 in the Supplement). In addition, GAD was found disproportionately in respondents with lower educational levels, lower household income, and Other employment status (mostly unemployed or disabled). These correlates were relatively modest in magnitude (odds ratio [OR], 1.1; 95% CI, 1.0-1.3 to OR, 1.8; 95% CI, 1.7-2.0) except for the markedly increased odds of GAD among younger cohorts (OR, 3.0; 95% CI, 2.7-3.3 to OR, 6.0; 95% CI, 5.1-7.0). The pattern of correlates was similar across country groups, although GAD was associated less consistently with educational level, household income, and employment status in middle-and lowincome countries.
Onset and Course
Generalized anxiety disorder typically begins in adulthood (eFigure in the Supplement). Onset before puberty was rare in these surveys, with only 5% of cases developing by age 13 years. There was a gradual, steady accumulation of new cases over the lifespan, with 25% of all cases emerging by 25 years, 50% of the cases emerging by 39 years, and 75% of the cases emerging by 53 years. Although the AOO distribution was shifted earlier for high-income countries (median AOO, 36 years) relative to middle-and low-income countries (median AOO, 43 years for both), the distributions were substantively similar across country groups (χ 2 2 =1. 9, P = .38).
Consistent with conceptualizations of GAD as a chronic disorder, nearly half of all lifetime cases still had the disorder in the 12 months before the interview (Table 1) . Generalized anxiety disorder was more persistent in low-income (59.5%) and middle-income (56.1%) countries than in high-income countries (45.9%). Around the world, persistence was higher for earlier-onset GAD cases, for individuals with lower educational levels and family income, and for those not employed outside the home (ie, Other status, homemaker) (eTable 2 in the Supplement).
Comorbidity
Most individuals with lifetime (81.9% [0.7%]) and 12-month (70.8% [1.2%]) GAD had 1 or more comorbid DSM-IV/CIDI disorders ( Table 2 ). The odds were highest for lifetime mood and anxiety disorders, lower for disruptive behavior disorders, and lowest for substance-related disorders. The single most common comorbid condition was major depressive disorder, which was found in 52.6% (0.9%) of lifetime cases and 40.9% (1.3%) of 12-month cases of GAD worldwide.
Role Impairment
Respondents with 12-month GAD reported a mean (SE) of 41.2 days (2.4) out of role due to GAD in the past year. Half (50.6%) of the 12-month cases reported severe functional impairment resulting from GAD ( Table 3 ). The rate of severe impairment was lower yet still substantial (35.3%) among individuals with GAD who had no comorbid disorders (eTable 3 in the Supplement).
The proportion of participants with severe GAD-related impairment was highest in high-income (54.5%), lower in middle-income (42.6%), and lowest in low-income (39.0%) countries. Generalized anxiety disorder was a more disabling disorder in some countries than others, with severe impairment reported by a small minority of persons with GAD in China (17.3% in Shenzhen, 21.8% in Beijing/Shanghai) and Mexico (28.7%) but by a large majority of those with GAD in the Netherlands (80.3%) and Romania (82.3%). Neverthe-less, the proportion of severely impaired persons was sizable in most countries (median, 48.6%; interquartile range, 39.4%-56.2%).
Treatment
Approximately half (49.2%) of respondents with 12-month GAD reported receiving some form of mental health treatment during the previous year (Table 4) . Treatment was sought disproportionately by those with comorbid disorders (55.8%) but was also sought by approximately one-third (32.4%) of respondents with GAD alone (eTable 4 in the Supplement). The treatment rate was higher in high-income (59.0%) than in middleincome (29.1%) or low-income (21.7%) countries. However, across countries, the overall pattern was of increasing use of services, particularly specialty mental health services, with increasing impairment due to GAD.
Discussion
The present findings shed new light on patterns of GAD around the globe. First, we showed that diagnostic changes from DSM-IV to DSM-5 yielded an influx of new GAD cases, as lifetime prevalence estimates reported herein are 37% to 90% higher than published estimates for DSM-IV GAD in the United States. 32, 33 In the current WMH surveys, lifetime prevalence is 37% higher and 12-month prevalence is 50% higher for DSM-5 than DSM-IV GAD (Ruscio AM, Hallion LS, Demyttenaere K, Lee S, Lim CCW. Abbreviations: GAD, generalized anxiety disorder; OR, odds ratio.
a The ratio of numerator to denominator numbers does not equal the reported percentages because the percentages are weighted.
b Proportion of respondents with lifetime DSM-5 GAD who also qualified for the lifetime DSM-IV disorder in each row.
c Based on separate logistic regression models using lifetime GAD to predict each lifetime comorbid disorder; all significant at P < .001.
d Proportion of respondents with 12-month DSM-5 GAD who also qualified for the 12-month DSM-IV disorder in each row.
e Based on separate logistic regression models using 12-month GAD to predict each 12-month comorbid disorder; all significant at P < .001.
f The surveys did not include a 12-month assessment of childhood-onset separation anxiety disorder.
g Includes bipolar I disorder, bipolar II disorder, or subthreshold bipolar disorder as defined by Merikangas et al. expected, these estimates reveal that the increase was substantial. The newly identified individuals, who previously were barred from a GAD diagnosis by a concomitant mood disorder, have been shown in outpatient samples to experience a particularly severe form of GAD with a high burden of comorbidity. 34, 35 Consistent with this account, we found that more than 80% of people with lifetime GAD experienced another lifetime disorder, most often major depressive disorder. Given the frequent occurrence of GAD during mood episodes and the implications of comorbidity for treatment, 36 these findings underscore the importance of systematic assessment and appropriate management of GAD in patients with mood disorders. Second, the prevalence of GAD varied widely across countries, with rates generally higher in higher-income countries. This means that the global prevalence of GAD may be considerably lower than the previous best-estimate rates of 6.2% (lifetime) and 2.6% (12-month), which were based exclusively on high-income countries. 37 This finding aligns with the broader pattern of higher rates of psychopathology in wealthier countries 38 that has variously been attributed to methodologic artifacts, differential reporting of mental illness, or differences in risk and protective factors across countries. 39-41 A further possibility specific to GAD is that cognitive symptoms of the disorder may be reported less frequently than somatic symptoms in developing countries, 42, 43 implying that clinically significant anxiety in those countries may be missed by the DSM-5 emphasis on worry. Another possibility is that, when worry is reported, it may focus on a single dominant concern (eg, financial worry) 44 or fail to be judged as excessive owing to genuinely difficult life circumstances. 45 A simple form of this explanation is contradicted by higher rates of GAD in persons of lower socioeconomic status who presumably have the most stress and fewest resources. A more nuanced form is that individual differences in the propensity to worry may be more evident under conditions of relative wealth and stability, such as those found in high-income countries, than under conditions of relative scarcity and instability, where worry may be expected and widespread. The prevalence of DSM-5 GAD was concentrated among individuals who were female, younger than 60 years, unmarried, not employed, less educated, and less affluent relative to national standards. Contrary to most mental disorders, 46 onset of GAD before adulthood was uncommon, occurring in fewer than 25% of the cases. Instead, new cases accrued gradually from puberty through 65 years. These findings are consistent with previous epidemiologic studies in high-income countries 32,47 and suggest that onset or recognition of the disorder is even later in lower-income countries. The relatively shallow AOO distribution seems unlikely to result from retrospective recall biases, as surveys of adolescents have yielded similar findings. 48,49 A more plausible explanation is that GAD may be triggered by stressful life events at any time in the lifespan, 50,51 accounting for the gradual accumulation of cases.
Another possibility is that a temperamental predisposition to worry, emerging early in life, does not cause marked distress or impairment until a significant stressor-or chronic stress of the sort associated with the socioeconomic profile characteristic of GAD-overwhelms the individual's capacity to keep worry in check. 52,53 Once GAD begins, it often persists: nearly half of the individuals with lifetime GAD met 12-month criteria for the disorder. However, persistence varied widely, with higher persistence reported in lower-income countries. Taken together, these findings provide mixed support for conventional views of GAD as a chronic condition present since early life. 54-57 Instead, we found that the GAD syndrome usually first emerges in adulthood and that its course, although often unremitting, differs substantially by country. Contrary to some characterizations of GAD as a disease of the "worried well," 1, 6 GAD was associated with marked disability. Half of the individuals with 12-month GAD reported severe disability in 1 or more life domains resulting from the disorder. Moreover, individuals reported a mean of more than 40 days in the past year when they were completely unable to work or carry out daily activities because of GAD. Finally, GAD was associated with significant help seeking, with approximately half of the individuals with 12-month GAD receiving treatment during the past year. Consistent with conceptions of comorbidity as a severity marker, 58 individuals whose GAD occurred with other disorders reported greater disability due to GAD and greater use of mental health services. However, even in the absence of other disorders, one-third of individuals with GAD reported severe impairment and treatment. These results extend prior findings of general health-related disabil- 9.6 (P < .001) 13 .0 (P < .001) a The ratio of numerator to denominator numbers does not equal the reported percentages because the percentages are weighted.
b Sheehan Disability Scale scores for severe impairment range from 7 to 10. Respondents rated the extent of interference with home management, work, close relationships, and social life on separate 0-to-10 scales and were assigned to a severity category based on their highest impairment rating across the 4 role domains.
c Proportion with severe role impairment in at least 1 of the 4 Sheehan Disability Scale role domains.
d χ 2 2 Test of homogeneity for variation in impairment severity across low-, middle-, and high-income countries.
ity and diminished quality of life in GAD 59-61 by quantifying the impairment resulting from GAD in each life domain, showing that impairment is substantial in developing as well as developed countries, and describing the association between impairment and treatment seeking across countries. Although GAD was impairing in all of the countries included in the present study, it was most impairing in highincome countries. This finding is particularly striking when contrasted against the greater frequency and persistence of GAD in individuals with lower socioeconomic status relative to national standards. The inverse associations with income at the individual vs national levels have been documented for many mental disorders and could reflect the influence of risk factors that vary with economic development. 62 For ex- a Empty cells indicate fewer than 5 cases. The ratio of numerator to denominator numbers does not equal the reported percentages because the percentages are weighted.
b Based on GAD-related impairment rated on the Sheehan Disability Scale. Sheehan Disability Scale scores were categorized as 1 to 3 (mild), 4 to 6 (moderate), and 7 to 10 (severe). Respondents rated the extent of interference with home management, work, close relationships, and social life on separate 0-to-10 scales and were assigned to a severity category based on their highest impairment rating across the 4 role domains.
c Includes psychiatrist, psychologist, or other mental health professional; social worker or counselor in a mental health specialty setting; use of a mental health helpline; or overnight admission for a mental health, drug, or alcohol problem, with a presumption of daily contact with a psychiatrist. d χ 2 2 Test of homogeneity for variation in treatment estimates across low-, middle-, and high-income countries. The test was performed when more than 1 stable cell (Ն5 cases) was available for comparison.
e Includes general practitioner, other medical physician, nurse, occupational therapist, or other health care professional not previously mentioned.
f Includes religious or spiritual advisor, or social worker or counselor in any setting other than a specialty mental health setting.
g Includes any other type of healer, such as herbalist or homeopath; participation in an internet support group; or participation in a self-help group.
h Respondents who sought any form of treatment listed above. ample, greater industrialization and urbanization in higherincome countries may result in fewer community supports (eg, extended family and religious community) to buffer the impact of stressful events or assist with role functioning. In addition, there may be greater demands on individuals in higherincome countries to achieve independence, occupational success, and social status in a competitive environment, increasing uncertainty and perceived pressure to meet high expectations.
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Limitations
Our large general population sample offered unprecedented statistical power and the opportunity to study GAD in parts of the world in which, to our knowledge, no previous data were available. Nevertheless, the study was limited in several respects. Assessment was performed with fully structured interviews administered by lay interviewers. Clinical reappraisal studies have shown good concordance with the SCID but indicate that CIDI-based prevalence estimates tend to be conservative. 22 Lifetime symptoms and disorder onset were reported retrospectively. Our measure of persistence could not distinguish chronic from recurrent cases and missed cases that resolved before the preceding 12 months. Finally, although the results varied systematically by country income strata, large differences in prevalence within strata suggest an influence of methodologic variation (eg, sample frames and/or response rates) or substantive factors (eg, sociocultural variables) not accounted for in our analyses.
Conclusions
Using data from 26 countries, we showed that DSM-5 GAD is a common disorder associated with considerable comorbidity and functional impairment. The disorder typically begins in adulthood, although its onset is later and its course is more persistent in less developed countries. Although GAD is found in similar subgroups within the countries examined, it is more prevalent and impairing in high-income than in lowor middle-income countries. Probing the mechanisms underlying these cross-national differences will advance understanding of GAD and inform debates regarding its validity and global relevance. 
